Drug Trial Radar · NCT03761849
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
899
Actual
Start
Jan 23, 2019
Primary completion
Mar 24, 2022
Study completion Mar 24, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)
Conditions
- Huntingtons Disease
Interventions
RO7234292Drug
Intrathecal injection
PlaceboDrug
Intrathecal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) Score-Z ScoreTime frame: Weeks 21 for ODC and 69 for NDC
- Change From Baseline in the Total Functional Capacity (TFC) ScoreTime frame: Weeks 21 for ODC and 69 for NDC
Locations
96 sites in 18 countries. Site status is shown where the registry gives one.
Uab Medicine
Birmingham, Alabama
Barrow Neurological Institute
Phoenix, Arizona
University of California San Diego
La Jolla, California
Stanford Univ Medical Center
Palo Alto, California
SC3 Research Group, Inc
Pasadena, California
University of California Davis Medical System
Sacramento, California
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado
Georgetown University; Research Division, Psychiatry
Washington D.C., District of Columbia
University of South Florida
Tampa, Florida
Northwestern University
Chicago, Illinois
John Hopkins University School of Medicine
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Dent Neurological Institute
Amherst, New York
Columbia University
New York, New York
University of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas Health Science Center at Houston; McGovern Medical School
Houston, Texas
University of Utah Clinical Neurosciences Center
Salt Lake City, Utah
Evergreen Health Care Center
Kirkland, Washington
Hospital Ramos Mejía
CABA, Argentina
INEBA
Capital Federal, Argentina
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
WESTMEAD HOSPITAL; Deparment of Neurology
Westmead, New South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Royal Melbourne Hospital; Department of Neurology
Parkville, Victoria, Australia
Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie
Innsbruck, Austria
Christian-Doppler-Klinik - Universitätsklinikum; Universitätskliniik für Neurologie
Salzburg, Austria
University of Alberta Hospital
Edmonton, Alberta, Canada
University of British Columbia Hospital; Division of Neurology
Vancouver, British Columbia, Canada
True North Clinical Research-Halifax
Halifax, Nova Scotia, Canada
Centre for Movement Disorders
North YORK, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Centre Hospitalier de l?Université de Montréal (CHUM)
Montreal, Quebec, Canada
Centro de Trastornos del Movimiento (CETRAM); CETRAM
Santiago, Chile
Aarhus Universitetshospital; Neurologisk Afdeling F, Neurogenetisk Afsnit
Aarhus N, Denmark
Rigshospitalet, Hukommelsesklinikken
København Ø, Denmark
CHU Angers, Batiement Larrey 2, Neurologie
Angers, France
Hopital Henri Mondor; Service de Neurologie
Créteil, France
Hopital Roger Salengro Service de Neurologie
Lille, France
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.